Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: A randomized, open-label study using a continuous glucose monitoring system

Endocrine Practice

Volumn 11, Issue 3, 2005, Pages 157-164

  Bode, Bruce W ^a   Steed, R Dennis ^a   Schleusener, Debra S ^b   Strange, Poul ^b  

^a ATLANTA DIABETES ASSOCIATES   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN GLARGINE; INSULIN LISPRO; ANTIDIABETIC AGENT; C PEPTIDE; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MALE; MULTIPLE DRUG DOSE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; AGED; ALGORITHM; BLOOD; HYPOGLYCEMIA; METABOLISM; MIDDLE AGED; MONITORING; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BLOOD GLUCOSE; C-PEPTIDE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; TREATMENT OUTCOME;

EID: 27744477604     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.3.157     Document Type: Article

References (15)

1. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49:2142-2148.
2. Pickup J, Keen H. Continuous subcutaneous insulin infusion in type 1 diabetes. BMJ. 2001;322:1262-1263.
3. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP (Study Group for the Development of Pump Therapy in Diabetes). Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care. 2000;23:1232-1235.
4. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996; 19:324-327.
5. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care. 1999;22:1779-1784.
6. Tsui E, Barnie A, Ross S, Parkes R, Zinman B. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care. 2001;24:1722-1727.
7. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26: 2598-2603.
8. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment [letter]. Diabetes Care. 2003;26:1321-1322.
9. Boland E, Weinzimer S, Ahern J, Steffen A, Tamborlane W. Randomized, prospective trial of CSII vs MDI with glargine in children: a preliminary report [abstract 192-OR]. Diabetes. 2003;52(Suppl 1):A45.
10. Bode B, Hirsch I, Hu P, Santiago O. Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine [abstract 439-P]. Diabetes. 2003;52(Suppl 1):A102.
11. King AB, Armstrong D. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine [letter]. Diabetes Care. 2003;26:1322.
12. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (U.S. Study Group of Insulin Glargine in Type 1 Diabetes). Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639-643.
13. User Guide: MiniMed* CGMS Corn-Station Software, Version 1.7A. Northridge, CA: MiniMed* Inc, January 3, 2001.
14. Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000;2:49-56.
15. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand. 1965;177:95-102.